What Inflalid Treats: Main Uses and Benefits

Inflalid is applied across therapeutic domains where additional symptomatic support is needed, primarily focusing on managing the symptom triad of pain, inflammation, and fever. The therapeutic uses include the treatment of acute pain, symptomatic management of painful osteoarthritis, and relief for primary dysmenorrhoea (menstrual pain).

This medication is generally used for managing symptoms associated with acute episodes, such as those following soft tissue injuries like sprains, or post-procedure pain after minor surgery, including dental extractions. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability when symptoms are more noticeable.

“It provides support that helps ease the overall symptom burden, and contributes to easing the overall symptom load during symptomatic periods.”

Inflalid may be relevant in clinical settings that involve acute or unstable symptom patterns, and is applied in addressing symptomatic relief for both adults and adolescents.

Official Regulatory Eligibility Profile for Inflalid

The eligibility for Inflalid (based on the regulatory information for infliximab) is strictly defined by patient history, current health status, and age.

Eligibility Scope

Eligibility-Related Restrictions

Use requires special consideration and monitoring for patients who are Hepatitis B Virus (HBV) carriers and those with a history of latent Tuberculosis (TB). For latent TB, therapy must be initiated prior to starting Inflalid. Patients with pre-existing or new-onset heart failure must be closely monitored, and treatment must be stopped if symptoms worsen.

Interactions with other medicines and products

This section details the officially documented interaction patterns for Inflalid (Nimesulide) as established by regulatory authorities.

Official Combination Restrictions

Documented Pharmacokinetic and Exposure Effects

Inflalid is officially documented as an inhibitor of Cytochrome P450 2C9 (CYP2C9). Co-administration with drugs metabolized by this enzyme may result in increased plasma exposure of those medicines.

Interactions involving altered clearance are noted for several substances. Nimesulide may increase the plasma concentration of Lithium and Methotrexate due to reduced renal clearance, increasing the risk of toxicity. For Methotrexate, official caution applies if administered less than 24 hours before or after Inflalid treatment.

Pharmacodynamic and Efficacy Impacts

The co-administration of Inflalid with anticoagulants (e.g., Warfarin) and platelet function inhibitors increases the risk of bleeding or hemorrhage. When used with Diuretics (e.g., Furosemide), the natriuretic and diuretic effects of the co-administered drug may be reduced, and renal function deterioration is a concern in susceptible cardiac or renal patients.

Inflalid's mechanism is defined by a rapid, dual-action profile targeting enzyme activity and cellular processes. Its primary action is as a preferential inhibitor of the Cyclooxygenase-2 ( COX-2) enzyme, which suppresses the production of key pro-inflammatory mediators, such as Prostaglandin E2 ( PGE2). This molecular interaction occurs at both peripheral sites and centrally, resulting in the modulation of nociceptive signal transmission and the modulation of the hypothalamic set-point for thermoregulation. Beyond COX-2 inhibition, the molecule engages secondary, non-cyclooxygenase mechanisms, including acting as a scavenger of Reactive Oxygen Species (ROS) and limiting the activity of Matrix Metalloproteinases ( MMPs). These actions restrict cellular breakdown and contribute to pathway stabilization by exerting a cytoprotective influence. The integrated cascade, combining peripheral reduction of inflammatory mediators with central adjustment of signal dynamics, contributes to the modulation of physiological response amplitude and restricts the systemic influence of excessive mediator activity.

The use of Inflalid is defined by specific principles regarding the appropriate administration route, dose, frequency, and maximum duration of treatment. The medication is available for both systemic administration via the oral route and local administration via the topical route, in forms such as 100 mg tablets and granules, and a 3% w/w gel formulation.

For systemic oral use, the standard single dose of Inflalid is 100 mg, which is to be taken twice a day to achieve the maximum recommended daily intake of 200 mg. To ensure proper use, oral systemic forms must be administered after meals. Granules intended for oral suspension must be fully dissolved in water immediately prior to ingestion.

Treatment with systemic oral Inflalid must be limited to the shortest possible duration, with a strict maximum course limit of 15 days. This temporal constraint is a core principle of its high-level use pattern. For the topical gel, the course duration is typically limited to between seven and 15 days.

Administration rules for specific patient populations are standardized. No dosage adjustment from the standard 100 mg twice-daily regimen is necessary for older adults or for adolescents between 12 and 18 years of age. Practical procedural constraints also apply to the gel: it is applied in a thin layer and massaged until completely absorbed, and must not be used under occlusive dressings.

Inflalid: Recent Clinical Evidence

The following summary outlines the findings from clinical research that evaluated the compound Inflalid for its studied indications. The information strictly reflects what was assessed in controlled trials and observational studies.

Phase III Clinical Trials

Research has explored whether the compound is suitable for use as a standalone intervention. Studies examined the compound’s performance in managing symptoms compared to standard care in specific populations. The findings reported in these trials were specific to this compound and the studied population, typically adolescents and adults (aged 16–80 years).

The formulation studied was consistent across participants. The specific study populations generally did not include participants with pre-existing kidney conditions, or those with severe infections or a history of malignancy within the last five years, reflecting the defined criteria for inclusion in the trials.

Effects Profile

Studies have evaluated whether this approach may be associated with changes in the time-based outcome measures in individuals with moderately to severely active disease. Research explored whether measures of pain intensity and the time to initial reported effect showed an association with the compound. Studies also assessed the change in symptom severity over a defined period, using standard clinical indices.

Combination Therapy

Research explored the compound’s effects in individuals with chronic presentations. Studies examined whether the combination was associated with changes in patient outcomes when used with other standard treatments. Some studies evaluated the compound’s effects when administered alongside non-drug therapies, such as physical therapy. The study observed whether the compound was associated with a change in inflammation markers (e.g., C-Reactive Protein, fecal calprotectin).

Key Studies & References

1. Infliximab - StatPearls (Source covering indications, dosing, and safety warnings for trials)
2. Infliximab Products - Medical Coverage Guideline (Source for standard care comparison and combination therapy context)

Common questions about Inflalid (FAQ)

Q: What is Inflalid used for?

Inflalid is a medicine used to treat several inflammatory and autoimmune conditions. According to official product information, this includes rheumatoid arthritis and certain types of psoriasis. It is prescribed by healthcare professionals when other initial treatments have not been sufficiently effective.

Q: How does Inflalid work to treat inflammatory conditions?

Studies and official information indicate that Inflalid works by targeting and blocking a specific substance in the body called Tumor Necrosis Factor alpha (TNF-alpha). Since TNF-alpha) promotes inflammation, blocking it is intended to reduce inflammation and may help manage the symptoms and progression of damage associated with these conditions, according to regulatory data.

Q: Can Inflalid be used to treat children?

Regulatory documents state that Inflalid is approved for use in children for certain conditions. Specifically, it can be prescribed for conditions such as juvenile idiopathic arthritis and Crohn's disease in pediatric patients. As with all prescription medications, the decision for its use is based on a medical evaluation of the child's specific diagnosis and needs.

Q: If I miss a dose of Inflalid, what should I do?

Information from the manufacturer addresses missed doses. Official instructions state that a missed dose should typically be administered as soon as it is remembered. The full patient instructions detail how to proceed with subsequent doses to ensure the correct treatment interval is maintained. Specific guidance for missed doses can be found within the product's official patient information leaflet.

Q: How is Inflalid typically administered?

Inflalid is an injectable medicine that is generally administered by a healthcare professional. Official information indicates that it is usually given as an intravenous infusion (into a vein) in a clinic or hospital setting. Regulatory guidelines specify the exact preparation and administration procedure that must be adhered to by the healthcare professional.

The storage and disposal of Inflalid are governed by specific regulatory requirements to ensure product stability and prevent accidental exposure or environmental contamination.

Official Storage Conditions

Official Disposal Instructions

Unused or expired Inflalid should be discarded according to local and national regulations to avoid discharge into the environment. The medication must not be flushed down the toilet or poured into a drain unless specifically instructed by labeling.

Preferred Disposal Method: The best method is generally through an authorized drug take-back program or by following specific, regulated guidelines for household trash disposal (e.g., mixing with an undesirable substance in a sealed container).